Key facts
- It has raised $35.7M; the latest was Early Stage VC ($33.3M) in Mar 2025.
- Notable investors include Korea Investment Partners, Capstone Partners Korea, Laplace Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for MVRIX
- ·The full record, as it builds
Funding rounds
No funding rounds for MVRIX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MVRIX
Operator of a biotechnology company intended for biologics discovery and development. The company develops new drugs based on platform technology related to membranes and viruses, enabling humans to be free from the attack of viruses and microorganisms.
- Sector
- Healthcare
- HQ
- Hwaseong, South Korea
- Founded
- 2021
- Website
- mvrix.co.kr/
- Ownership
- Privately Held (backing)
MVRIX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MVRIX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MVRIX in its N-PORT filings yet. We sweep new filings monthly.